JP6069663B2 - 抗炎症医薬製品 - Google Patents

抗炎症医薬製品 Download PDF

Info

Publication number
JP6069663B2
JP6069663B2 JP2014516041A JP2014516041A JP6069663B2 JP 6069663 B2 JP6069663 B2 JP 6069663B2 JP 2014516041 A JP2014516041 A JP 2014516041A JP 2014516041 A JP2014516041 A JP 2014516041A JP 6069663 B2 JP6069663 B2 JP 6069663B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
residue
present disclosure
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014516041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519526A (ja
JP2014519526A5 (https=
Inventor
アンジェロ・ピー・コンサルボ
ノーザー・エム・メータ
マウロ・ペレッティ
ジェスモンド・ダリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resother Pharma AS
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Publication of JP2014519526A publication Critical patent/JP2014519526A/ja
Publication of JP2014519526A5 publication Critical patent/JP2014519526A5/ja
Application granted granted Critical
Publication of JP6069663B2 publication Critical patent/JP6069663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014516041A 2011-06-15 2012-06-15 抗炎症医薬製品 Active JP6069663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161497270P 2011-06-15 2011-06-15
US61/497,270 2011-06-15
PCT/US2012/042699 WO2012174397A2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products
US13/524,381 2012-06-15
US13/524,381 US9102753B2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Publications (3)

Publication Number Publication Date
JP2014519526A JP2014519526A (ja) 2014-08-14
JP2014519526A5 JP2014519526A5 (https=) 2015-07-30
JP6069663B2 true JP6069663B2 (ja) 2017-02-01

Family

ID=47357770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516041A Active JP6069663B2 (ja) 2011-06-15 2012-06-15 抗炎症医薬製品

Country Status (12)

Country Link
US (2) US9102753B2 (https=)
EP (2) EP3533457B1 (https=)
JP (1) JP6069663B2 (https=)
CN (1) CN103764669B (https=)
AU (1) AU2012271453B2 (https=)
BR (1) BR112013032088B1 (https=)
CA (1) CA2839298C (https=)
DK (1) DK2720707T3 (https=)
ES (1) ES2712805T3 (https=)
HU (1) HUE042929T2 (https=)
PL (1) PL2720707T3 (https=)
WO (1) WO2012174397A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
PL4200319T3 (pl) 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
CN118891273A (zh) 2022-02-23 2024-11-01 雷索特制药股份有限公司 膜联蛋白a1衍生的多肽类似物
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
US6086018A (en) 1997-12-09 2000-07-11 Mcdonnell Douglas Corporation Interlocking assembly system for an aircraft cabin
US20090163578A1 (en) * 2004-10-01 2009-06-25 University Of Medicine And Dentistry Of New Jersey Novel modification of immunomodulatory protein
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物
US8691764B2 (en) * 2007-03-28 2014-04-08 The Research Foundation For The State University Of New York Inhibitors of NF-κB activity
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US8940697B2 (en) * 2009-10-16 2015-01-27 Duke University Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with Annexin A1 short peptide
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products

Also Published As

Publication number Publication date
EP3533457B1 (en) 2021-08-11
CN103764669B (zh) 2017-08-15
ES2712805T3 (es) 2019-05-14
US20150315256A1 (en) 2015-11-05
US9102753B2 (en) 2015-08-11
BR112013032088B1 (pt) 2020-11-24
PL2720707T3 (pl) 2019-06-28
HUE042929T2 (hu) 2019-07-29
CA2839298C (en) 2021-05-18
CN103764669A (zh) 2014-04-30
DK2720707T3 (en) 2019-04-08
AU2012271453A1 (en) 2013-12-19
CA2839298A1 (en) 2012-12-20
EP3533457A1 (en) 2019-09-04
EP2720707B1 (en) 2018-12-19
WO2012174397A2 (en) 2012-12-20
US10072055B2 (en) 2018-09-11
WO2012174397A3 (en) 2013-02-28
US20130072446A1 (en) 2013-03-21
JP2014519526A (ja) 2014-08-14
EP2720707A4 (en) 2015-05-06
BR112013032088A2 (pt) 2016-11-22
EP2720707A2 (en) 2014-04-23
AU2012271453B2 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
JP6069663B2 (ja) 抗炎症医薬製品
JP7621728B2 (ja) プロテアーゼ活性化受容体２のモジュレーター
WO2009019531A2 (en) Bioactive peptides and method of using same
TW201717996A (zh) 長效胜肽類似物
JP4471968B2 (ja) 毒素に対するｌｌ−３７由来のペプチド性阻害剤
KR20220117319A (ko) 레트로-인버소 펩타이드
WO2017149098A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
EP3419994B1 (en) Peptide inhibitors of calcium channels
CN107106643A (zh) 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽
JP2024545747A (ja) ペンタペプチドおよびその用途
WO2022047225A2 (en) Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases
JP2003513660A (ja) ヘッジホッグ融合タンパク質及び利用
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
JP2011516450A (ja) 髄膜炎に対するデフェンシンの使用
JP2006512308A (ja) 糖尿病関連及び／又は動脈低治癒性創傷の治療及び／又は予防のための、α−１−アンチキモトリプシン（ａｎｔｉｃｈｙｍｏｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸の、α−１−アンチトリプシン（ａｎｔｉｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸と組み合わせた使用
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
CA3005029C (en) Protease-activated receptor-2 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161208

R150 Certificate of patent or registration of utility model

Ref document number: 6069663

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250